Mirum Pharmaceuticals, Inc.

This biopharmaceutical company specializes in developing and commercializing therapeutic treatments for rare and orphan diseases with significant unmet medical needs. Its commercial portfolio features three approved prescription medicines: Livmarli, an ileal bile acid transporter inhibitor indicated for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; Cholbam, formulated for pediatric and adult patients with bile acid synthesis and peroxisomal disorders; and Ctexli, an approved therapy for cerebrotendinous xanthomatosis. The firm also maintains an active clinical pipeline pursuing expanded indications and investigating product candidates for cholestatic liver conditions, chronic viral infections, and neurocognitive disorders. Its therapies primarily serve specialized patient groups managed through medical providers and dedicated healthcare channels.

The company operates globally through direct commercial organizations in the United States, Canada, and select European countries, supplemented by third-party license and distribution partnerships across international territories. In the United States, specific commercial products are distributed via a dedicated specialty pharmacy. The provided text contains no information regarding the company's headquarters location.

Summary of the business section of Mirum Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 372 employees, of whom 369 are full time, consisting of clinical, research, operations, finance and business development personnel.”